Archive · 26 Jan 2026
AIIMS leads fight against superbugs
Doctors at AIIMS in Delhi are working hard to fight superbugs, which are bacteria that can resist antibiotics.
These superbugs are becoming a big problem because they make infections harder to treat.
AIIMS is doing research to understand how these bacteria become resistant and to find better ways to diagnose and treat infections.
They are also working on new methods to stop the spread of these superbugs, like using special tests and new treatments.
One of their big successes is a new treatment for tuberculosis that works much faster than old ones.
The doctors say that to really stop superbugs, we need to use antibiotics carefully, clean hospitals well, and keep doing research.
AIIMS Delhi is leading research to combat antimicrobial resistance (AMR) with 15 ongoing projects.
AMR is a serious global threat, projected to cause 10 million deaths by 2050, with India bearing a heavy burden.
Research focuses on improving diagnosis, targeted therapy, and reducing unnecessary antibiotic use.
Innovative approaches include CRISPR-Cas9 gene editing, quorum sensing inhibitors, and advanced genetic testing.
A breakthrough in TB treatment, the BPaL-M regimen, shortens therapy to six months with high success rates.
- Who
- Researchers at AIIMS, Delhi, led by Dr. Bimal Kumar Das and Dr. Hitender Gautam
- What
- Efforts to combat antimicrobial resistance (AMR) and improve diagnostic and treatment methods
- When
- Ongoing research and projects, with a focus on current and future impacts of AMR
- Where
- All-India Institute of Medical Sciences (AIIMS), Delhi, India
- Why
- To address the growing threat of AMR, which is causing increasing deaths and complicating treatments
- Institution
- All-India Institute of Medical Sciences (AIIMS), Delhi
- Primary Concern
- Antimicrobial Resistance (AMR)
- Global Impact
- 10 million deaths projected by 2050
- India's Burden
- 2.97 lakh deaths linked to AMR in 2019
- Research Focus
- 15 projects on resistance patterns, diagnosis, and antibiotic use
- Key Pathogens
- Salmonella typhi, E. coli, ESKAPE pathogens
- Innovative Approaches
- CRISPR-Cas9, quorum sensing inhibitors, biomarker-based diagnostics
- TB Treatment Breakthrough
- BPaL-M regimen shortens therapy to six months